Predict your next investment

Corporation
HEALTHCARE | Disease Diagnosis
ambrygen.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Valuation

$0000 

About Ambry Genetics

Ambry Genetics offers a comprehensive suite of genetic testing solutions for inherited and non-inherited diseases as well as for numerous clinical specialties, including oncology, cardiology, pulmonology, neurology, and general genetics. The company is recognized as a leader in diagnostic solutions for hereditary conditions in the United States, by having performed more than one million genetic tests and identified more than 45,000 mutations in at least 500 different genes. Ambry is known as a pioneer and thought leader in genetic testing being the first laboratory in the world to offer such tests as hereditary cancer panels and clinical exome sequencing.

Ambry Genetics Headquarter Location

15 Argonaut

Aliso Viejo, California, 92656,

United States

949-900-5500

Latest Ambry Genetics News

In people ordering genetic CV tests, positive result rate varies with age

Sep 30, 2021

Source: Schultz C, et al. Presented at: National Lipid Association Scientific Sessions; Sept. 24-26, 2021; Orlando, Fla. (hybrid meeting). Disclosures: Schultz is an employee of Ambry Genetics. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio Among people who ordered a genetic test for dyslipidemia, younger people were more likely to have a positive result than older people, according to a presentation at the National Lipid Association Scientific Sessions. Catherine Schultz, MS, CGC, specialty genomic science liaison at Ambry Genetics, presented results of a study on ordering trends and testing outcomes for more than 3,000 participants who underwent genetic testing for dyslipidemias at Ambry from 2014 to 2020. Source: Adobe Stock “The clinical indication and utility of genetic testing is very well established, understood and recognized in not only the cardiovascular and lipidemia communities, but across the broader genetics community,” she said during the presentation. “This has been illustrated by the inclusion of familial hypercholesterolemia (FH) as a disease state, which should be reported as an incidental finding following exome sequencing or genome sequencing through recommendations from the American College of Medical Genetics. However, these monogenic dyslipidemias remain underdiagnosed and poorly recognized in patients, despite the wider acknowledgement in the genetics and cardiovascular communities.” Participants were stratified based on whether their testing outcome was positive, negative or inconclusive. Schultz said 31.42% of participants received a positive report. “Targeted gene sequencing and single-site analysis had the highest diagnostic yield, indicating that a strong family history or very, very high clinical suspicion for that particular gene of interest was fueling this particular ordering trend,” she said. “We also saw that patients were receiving inconclusive results across the board, primarily in next-generation sequencing panels, allowing us to identify more than just a known targeted mutation. These patients had a variant of unknown significance, meaning that there is not significant evidence to classify that as either pathogenic in causing disease or benign. These particular types of variants require additional study.” Although most participants were older than 36 years, “we saw a significant difference in patients under the age of 18 receiving a positive result,” Schultz said. “In looking at FH testing, we saw a negative correlation between a patient’s age and the likelihood of receiving a positive diagnosis (R2 = 0.9825). This can be explained by many different reasons. Primarily, we feel that patients with younger age undergoing testing are likely doing so due to a strong family history or known familial mutation that prompted cascade screening. Therefore, these patients have a much higher pretest probability of testing positive, at 50% based on recurrence, as opposed to patients in the more generalized screening population for dyslipidemias. Additionally, younger patients may be presenting to clinic with much more striking and severe disease states, prompting that referral, compared with older patients who may present with more general dyslipidemias that could be associated with genetic contributions or environmental factors.” Among those who ordered a custom next-generation panel, 36.27% included at least one lipid gene, and of those, 31.69% included genes associated with other cardiac factors but not dyslipidemia, Schultz said, “indicating that patients may be undergoing genetic testing for more than one primary indication of some type of cardiovascular disease , or these providers are interested in knowing what the risk associated with a hereditary dyslipidemia may be.” Read more about

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ambry Genetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ambry Genetics is included in 1 Expert Collection, including Omics.

O

Omics

1,029 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Ambry Genetics Patents

Ambry Genetics has filed 3 patents.

The 3 most popular patent topics include:

  • Bioinformatics
  • Breast cancer
  • DNA
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/19/2002

6/22/2010

Cystic fibrosis, Genetics, Molecular biology, Biotechnology, Mutation

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

11/19/2002

00/00/0000

00/00/0000

Grant Date

6/22/2010

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Cystic fibrosis, Genetics, Molecular biology, Biotechnology, Mutation

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.